Renal Cell Carcinoma

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

By

Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Carmena Trial: Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Sunitinib May Eliminate the Need for Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

By

The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

Pegilodecakin Plus Anti-PD-1 Agents May Be Effective in Metastatic Renal Cell Carcinoma

By

Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Diabetes Ups Kidney Cancer Risk in Women

Diabetes Ups Kidney Cancer Risk in Women

By

Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Renal Cell Carcinoma:  How Biomarkers Could Affect Drug Development

Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

By

An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

Cabozantinib Effective in Real-World Analysis for Relapsed Metastatic Renal Cell Carcinoma

By

The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

By

Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

By

Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

FDA Approves Nivolumab With Ipilimumab for Renal Cell Carcinoma

By

Approval was based on results from the randomized phase 3 CheckMate-214 study.

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC

By

The standard schedule is associated with AEs including grade 3 to 4 fatigue, HFS, and diarrhea.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Combinations: The Future of Renal Cell Carcinoma Treatment?

Combinations: The Future of Renal Cell Carcinoma Treatment?

By

Several phase 3 clinical trials are likely to identify new frontline standards of care.

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma

By

Previous studies showed that combination therapy with nivolumab and ipilimumab has promising efficacy for various cancers, including RCC, compared with either agent alone.

Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma

Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma

By

VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.

Renal Cell Carcinoma Treatment Regimens

Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

By

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

By

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

By

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

Axitinib With Avelumab Shows Promise as First-Line Therapy for Renal Cell Carcinoma

By

Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.

Curbing Regulatory Capture: A Q&A With Bishal Gyawali, MD, PhD

Curbing Regulatory Capture: A Q&A With Bishal Gyawali, MD, PhD

By

Cancer Therapy Advisor asked Dr Gyawali, who coauthored a viewpoint just published in JAMA Oncology, to discuss the FDA's approval of sunitinib, and whether it is an example of what he calls "regulatory capture" in medicine.

Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

By

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma

PPI, H2RA Use With Pazopanib Does Not Affect PFS, OS in Renal Cell Carcinoma

By

Previous studies found that an elevated pH environment leads to nearly a 40% reduction in pazopanib exposure.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs